Fly News Breaks for February 28, 2020
SAGE
Feb 28, 2020 | 07:11 EDT
Mizuho analyst Vamil Divan lowered the firm's price target on Sage Therapeutics to $58 from $69 and keeps a Neutral rating on the shares. The analyst has been expecting Zulresso's rollout to be challenging but notes company commentary suggests it may be even slower than expected.
News For SAGE From the Last 2 Days